Abstract
The pathogenesis of rheumatoid arthritis is mainly driven by NF-κB-mediated production of cytokines, such as TNF-α. We report herein that the orally available imidazoline-based NF-κB inhibitor, TCH-013, was found to significantly reduce TNF-α signaling and attenuate collagen antibody induced arthritis in BALB/c mice.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Administration, Oral
-
Animals
-
Arthritis, Rheumatoid / chemically induced
-
Arthritis, Rheumatoid / drug therapy*
-
Collagen
-
Dose-Response Relationship, Drug
-
Imidazoles / administration & dosage
-
Imidazoles / pharmacology*
-
Mice
-
Mice, Inbred BALB C
-
Molecular Structure
-
NF-kappa B / antagonists & inhibitors
-
Signal Transduction / drug effects
-
Structure-Activity Relationship
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
-
Tumor Necrosis Factor-alpha / metabolism
Substances
-
Imidazoles
-
NF-kappa B
-
TCH-013
-
Tumor Necrosis Factor-alpha
-
Collagen